Quantcast
Last updated on April 20, 2014 at 8:28 EDT

Latest Augmenix Inc. Stories

2011-05-12 07:00:00

PALO ALTO, Calif. and WALTHAM, Mass., May 12, 2011 /PRNewswire/ -- Varian Medical Systems, Inc. (NYSE: VAR), the world's leading supplier of medical technology for treating cancer with radiotherapy, and privately-held Augmenix, Inc. today announced that they have reached an agreement under which Varian will make a $15 million minority equity investment in Augmenix, a company that is developing hydrogel products to improve outcomes in radiation oncology. The agreement also provides Varian...

2010-08-11 12:53:00

WALTHAM, Mass., Aug. 11 /PRNewswire/ -- Augmenix, Inc. announced today that Prof. Michael Eble and Dr. Michael Pinkawa of the Aachen University Hospital, Aachen, Germany, performed a commercial implantation of the company's CE Mark approved SpaceOAR(TM) System. The SpaceOAR hydrogel (from spacing Organs At Risk) is designed to be a tissue compatible, absorbable spacer to reduce radiation injury to healthy tissues. "The potential for radiation injury to nearby healthy tissues is always...

2009-10-16 15:50:00

WALTHAM, Mass., Oct. 16 /PRNewswire/ -- Augmenix announced today that it has closed a $6.1 million Series B financing. The round was led by Ascension Health Ventures (AHV) in St. Louis, Mo., with continued participation by existing investors, Versant Ventures and Pinnacle Ventures. Also participating were Catalyst Health Ventures and several private investors. "The field of radiation oncology has traditionally been of a large capital equipment mindset in solving problems. Augmenix...